AI will be difference between winners and losers says new Temenos report | FF News at Sibos

We speak to Temenos Chief Strategy Officer, Kanika Hope, at Sibos 2023 in Toronto, to find out more about their recent Economist Impact report . According to the report, which interviewed bankers acro

Website link :https://adquash.com/news_q.php?str=AI_will_be_difference_between_winners_and_losers_says_new_Temenos_report_|_FF_News_at_Sibos_436

Bevacizumab biosimilar by Gedeon Richter for Metastatic Breast Cancer: Likelihood of Approval

Bevacizumab biosimilar is under clinical development by and currently in Phase I for Metastatic Breast Cancer. According to GlobalData, Phase I drugs for Metastatic Breast Cancer have an 82% phase tra

Website link :https://adquash.com/news_q.php?str=Bevacizumab_biosimilar_by_Gedeon_Richter_for_Metastatic_Breast_Cancer:_Likelihood_of_Approval_693

CBM-588 by Miyarisan Pharmaceutical for Hematopoietic Stem Cell Transplantation: Likelihood of Approval

CBM-588 is under clinical development by Miyarisan Pharmaceutical and currently in Phase I for Hematopoietic Stem Cell Transplantation. According to GlobalData, Phase I drugs for Hematopoietic Stem Ce

Website link :https://adquash.com/news_q.php?str=CBM-588_by_Miyarisan_Pharmaceutical_for_Hematopoietic_Stem_Cell_Transplantation:_Likelihood_of_Approval_695

Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval

Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung

Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Non-Small_Cell_Lung_Cancer:_Likelihood_of_Approval_697

Golidocitinib by Dizal (Jiangsu) Pharmaceutical for Natural Killer Cell Lymphomas: Likelihood of Approval

Golidocitinib is under clinical development by Dizal (Jiangsu) Pharmaceutical and currently in Phase II for Natural Killer Cell Lymphomas. According to GlobalData, Phase II drugs for Natural Killer Ce

Website link :https://adquash.com/news_q.php?str=Golidocitinib_by_Dizal_(Jiangsu)_Pharmaceutical_for_Natural_Killer_Cell_Lymphomas:_Likelihood_of_Approval_700

Epcoritamab by Genmab for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

Epcoritamab is under clinical development by and currently in Phase II for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Refractory Chronic Lymphocytic Leu

Website link :https://adquash.com/news_q.php?str=Epcoritamab_by_Genmab_for_Refractory_Chronic_Lymphocytic_Leukemia_(CLL):_Likelihood_of_Approval_701

NKX-019 by Nkarta for Follicular Lymphoma: Likelihood of Approval

NKX-019 is under clinical development by and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 82% phase transition success rate (PTS

Website link :https://adquash.com/news_q.php?str=NKX-019_by_Nkarta_for_Follicular_Lymphoma:_Likelihood_of_Approval_707

NKX-019 by Nkarta for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval

NKX-019 is under clinical development by and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to GlobalData, Phase I drugs for Waldenstrom Macroglobulinem

Website link :https://adquash.com/news_q.php?str=NKX-019_by_Nkarta_for_Waldenstrom_Macroglobulinemia_(Lymphoplasmacytic_Lymphoma):_Likelihood_of_Approval_708

BNT-142 by BioNTech for Peritoneal Cancer: Likelihood of Approval

BNT-142 is under clinical development by and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR)

Website link :https://adquash.com/news_q.php?str=BNT-142_by_BioNTech_for_Peritoneal_Cancer:_Likelihood_of_Approval_712

BNT-142 by BioNTech for Fallopian Tube Cancer: Likelihood of Approval

BNT-142 is under clinical development by and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase II drugs for Fallopian Tube Cancer have a 41% phase transition success rate

Website link :https://adquash.com/news_q.php?str=BNT-142_by_BioNTech_for_Fallopian_Tube_Cancer:_Likelihood_of_Approval_713

Imetelstat sodium by Geron for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Imetelstat sodium is under clinical development by and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20%

Website link :https://adquash.com/news_q.php?str=Imetelstat_sodium_by_Geron_for_Relapsed_Acute_Myeloid_Leukemia:_Likelihood_of_Approval_714

How was mRNA research used to fight COVID? | Explained

The story so far: On October 2, Nobel Prize week began with the 2023 Prize in Physiology or Medicine being awarded to Katalin Karikó and Drew Weissman. They were awarded the prize for their “discov

Website link :https://adquash.com/news_q.php?str=How_was_mRNA_research_used_to_fight_COVID_|_Explained_204